CAT# | PPO-H007 |
Application | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response, Patient stratification, Qualification of immune responses |
Purity | >70% (HPLC-MS) |
Size | 2 aliquots of 13 peptide pools containing 1μg per peptide /tube | Format | Freeze dried in micro tube rack with individual vials. | Topics | Infection, Cancer, Hodgkin's lymphoma, Burkitt's lymphoma, Nasopharyngeal carcinoma, Dermatomyositis, Systemic lupus erythematosus, Rheumatoid arthritis, Sj?gren's syndrome, Multiple sclerosis | NumberOfPeptides | 2043 | Organism | Epstein-Barr virus (HHV-4) | Specifications | Peptide scan (15mers with 11 aa overlap) | Protein Name | Selected proteins | References | 1."PepMixTM Peptide Pools for Clinical Applications: T cell therapy for viral infections after hematopoietic stem cell transplant" Leen et al, Application Note (2012) 2."T-cell Therapy for EBV-Associated Nasopharyngeal Carcinoma: Preparative Lymphodepleting Chemotherapy Does not Improve Clinical Results". Secondino et al., Ann. Onc. (2012) 3.Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals Tomaras et al., Journal of Virology (2011) 4."Effective and Long-term Control of EBV PTLD After Transfer of Peptide-Selected T Cells". Moosmann et al., BLOOD (2010) 5."Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma". Louis et al., J Immunother (2010) |
CAT# | Product Name | M.W | Molecular Formula | Inquiry |
---|---|---|---|---|
PPO-H132 | HEV (ORF3) | Inquiry | ||
PPO-H060 | Influenza A (Neuroamidase /California (H1N1) | Inquiry | ||
PPO-H126 | CyCMV (TP-UL83) | Inquiry | ||
PPO-H062 | RSV (Fusion glycoprotein F0) | Inquiry | ||
PPO-H019 | EBV (GP350/GP340) | Inquiry |
CAT# | Product Name | M.W | Molecular Formula | Inquiry |
---|---|---|---|---|
10-101-20 | Goserelin Acetate | 1269.43 | C59H84N18O14 | Inquiry |
10-101-59 | Liraglutide | 3751.2 | C172H265N43O51 | Inquiry |
R1574 | Octreotide | 1019.24 | C₄₉H₆₆N₁₀O₁₀S₂ | Inquiry |
10-101-139 | Myrcludex B | Inquiry | ||
10-101-285 | Teduglutide | 3752.08 | C164H252N44O55S | Inquiry |
R1847 | Sermaglutide | 4114 | C187H291N45O59 | Inquiry |
R1961 | Carbetocin | 988.2 | C45H69N11O12S | Inquiry |
Required fields are marked with *
×Required fields are marked with *
×* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).
Creative Peptides has accumulated a huge library of peptide knowledge including frontier peptide articles, application of peptides, useful tools, and more!
Guangxitoxin 1E is a KV2.1 and KV2.2 specific channel blocker (IC50 values are 1-3 nM). The experimental results ...
Obestatin is a 23-amino acid peptide hormone produced in specific epithelial cells of the stomach and small inte ...
Pep2m, a peptide inhibitor of GluA2 subunit binding to NSF, reduces α-amino- 3-hydroxy-5-methyl-isoxazolepropion ...
Secretin belongs to the vasoactive intestinal peptide/pituitary adenylate cyclase activating peptide family an ...
ICl 154,129 is a new compound that shows selectivity as an antagonist of [Leu5]enkephalin and [D-AIa2, D-Leu5]en ...